MIRNA Therapeutics, Inc. (NASDAQ: MIRN) was founded in the second half of 2007 as a wholly-owned subsidiary of Asuragen, Inc., and was independent until the end of 2009. It is headquartered in Austin, Texas, and employs 24 full-time employees (6/30/2015) , Is a clinical stage biopharmaceutical company, focusing on the development of a wide range of microRNA-based small molecule tumor therapeutics (anticancer drugs).
MIRNA Therapeutics (MIRN):
MicroRNA is a naturally occurring short ribonucleic acid, RNA, molecule or oligonucleotide, which plays a key role in the biological regulation process. Even the wrong expression of a single microRNA can promote the development of diseases and the occurrence of tumors. Therefore, it is usually In cancer patients, microRNA is reduced. Scientists at MIRNA Therapeutics and other leading academic institutions have determined that a large number of microRNAs play a key role in tumor suppression, preventing normal cell canceration and proper immune surveillance.
MIRNA Therapeutics is researching an innovative treatment method called “microRNA replacement therapy” aimed at restoring tumor suppressor activity and allowing people to naturally produce an appropriate tumor immune response. Among them, the company’s main product candidate is MRX34 for this field.
MRX34 is a mimic of naturally occurring microRNA (microRNA), which is encapsulated in lipid nanoparticle preparations. It is the industry’s first mimic microRNA preparation for microRNA to enter clinical trials. It is currently undergoing phase I clinical trials and obtained Show preliminary clinical evidence of anti-tumor activity. It is expected that the phase I clinical trial of dose escalation will be completed before the end of 2015, and there will be multiple research data for different types of tumors released at the end of 2016. At that time, the scope of volunteer patients will be expanded and a larger range of clinical trials will be conducted.
So far, MIRNA Therapeutics has observed tumor shrinkage of more than 30% in 2 patients with stage 4 cancer in patients with MRX34. One of them was a patient whose primary liver cancer eventually metastasized to the lung, and the other was a melanoma patient. All patients are in stage IV cancer.
MIRNA Therapeutics (MIRN) investment:
MIRNA Therapeutics, Inc. submitted its IPO prospectus on 8/24/2015. It plans to raise 80.21 million US dollars with an issue price of 13-15 US dollars. It is listed on NASDAQ, and the stock code is MIRN.
On October 6, 2015, MIRNA Therapeutics, Inc. announced the termination of the listing process.
Company official website: www.mirnarx.com